Blood samples to test the TST79 molecular test for cancer patients
Official title: Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test at the Department of Pathology at the Grand Hôpital de Charleroi.
Run by Grand Hôpital de Charleroi · NCT07868640 · Data updated 2026-11-12
Doctors will take blood from people with various cancers to see if the TST79 blood test can detect mutations in circulating DNA.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Grand Hôpital de Charleroi Academic / other |
| Locations | 1 site (Charleroi, Hainaut) |
| Status | Recruiting |
| Started | September 15, 2026 |
| Main results expected | December 30, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT07868640 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with one of several specified cancers who are receiving care at GHDC and are invited to donate blood for ctDNA testing.
✕Probably not a fit
Patients whose tumors do not shed detectable ctDNA or whose mutations are not covered by the TST79 panel may not benefit from this testing.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial involves collecting blood from cancer patients to test a commercial ctDNA assay (TST79) that screens 79 genes for different mutation types. The goal is to validate how well the test detects mutations in plasma alongside standard cancer care. Analyses focus on circulating tumor DNA rather than tumor tissue, reflecting advances in molecular cancer diagnostics. The study uses a gene-alteration pairing approach to evaluate the test within routine care settings at Grand Hôpital de Charleroi.
Why it matters
Potential benefit: If successful, the test could help guide personalized treatment decisions by identifying actionable mutations from a simple blood sample.
How similar studies have gone: Prior studies in ctDNA testing have shown promise for detecting mutations across multiple cancer types, supporting continued validation of broad gene panels.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with the following types of cancer may be invited to donate blood as part of one of two approaches: * lung adenocarcinoma * colorectal adenocarcinoma * breast carcinoma * prostate adenocarcinoma * clear cell renal cell carcinoma * GIST/gastrointestinal stromal tumour * melanoma * urothelial carcinoma * endometrial carcinoma * high-grade ovarian carcinoma
Where it's running
-
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium Recruiting
Study contacts
- Principal investigator: David Schröder, MD, PhD — Grand Hôpital de Charleroi
- Study coordinator: David Schröder, MD, PhD
- Email: david.schroder@ghdc.be
- Phone: 0032 60
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.